AstaZeneca seeks to show strength against Pfizer with forecast

AstraZeneca, the target of a takeover bid of more than $100 billion by Pfizer, forecast long-term sales growth as it seeks to convince investors that it can succeed as a standalone drugmaker.

6th May, 2014

AstraZeneca, the target of a takeover bid of more than $100 billion by Pfizer, forecast long-term sales growth as it seeks to convince investors that it can succeed as a standalone drugmaker.

AstraZeneca will have more than $45 billion in yearly revenue by 2023, following “strong and consistent” sales growth starting in 2017, the London-based company said today in a statement. Operating leverage will probably “result in core earnings growth in excess of revenue growth during...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The year in review

Legacy Richie Oakley 11 months ago

Newsround: What Thursday’s papers say

Legacy Leanna Byrne 5 years ago

More cycle routes, expansion of Luas to Bray and new bus network proposed

Legacy Digital Desk 5 years ago